Sentiment-Signal
26,9
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
72.1
13D-Filing vorhanden
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 21.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | . Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Unternehmen & Branche
| Name | ALUMIS INC. |
|---|---|
| Ticker | ALMS |
| CIK | 0001847367 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,86 Mrd. USD |
| Beta | -0,61 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 24,050,000 | -243,325,000 | -2.86 | 411,940,000 | 301,297,000 |
| 2025-09-30 | 10-Q | 2,066,000 | -110,752,000 | -1.06 | 488,014,000 | 384,773,000 |
| 2025-06-30 | 10-Q | 2,666,000 | 59,321,000 | 0.77 | 610,925,000 | 485,327,000 |
| 2025-03-31 | 10-Q | 17,389,000 | -98,963,000 | -1.82 | 261,298,000 | 168,314,000 |
| 2024-12-31 | 10-K | -294,233,000 | -10.38 | 340,992,000 | 260,104,000 | |
| 2024-09-30 | 10-Q | -93,117,000 | -1.73 | 412,559,000 | 348,389,000 | |
| 2024-06-30 | 10-Q | -56,508,000 | -23.10 | 265,179,000 | -438,755,000 | |
| 2024-03-31 | 10-Q | -49,849,000 | -21.03 | -385,926,000 | ||
| 2023-12-31 | 10-K | -154,993,000 | -72.08 | 89,612,000 | -339,260,000 | |
| 2023-09-30 | 10-Q | -43,377,000 | -19.76 | -303,072,000 | ||
| 2023-06-30 | 10-Q | -36,289,000 | -17.13 | -262,353,000 | ||
| 2023-03-31 | 10-Q | -36,027,000 | -228,639,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-09 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 588,235 | 17.00 | 9,999,995.00 | +848,5% | |
| 2026-01-08 | Foresite Capital Management VI LLC | 10% Owner | Open Market Purchase | 294,117 | 17.00 | 4,999,989.00 | +424,2% | |
| 2026-01-08 | Tananbaum James B. | Director, 10% Owner | Open Market Purchase | 117,647 | 17.00 | 1,999,999.00 | +169,7% | |
| 2026-01-08 | Tananbaum James B. | Director, 10% Owner | Open Market Purchase | 294,117 | 17.00 | 4,999,989.00 | +424,2% | |
| 2026-01-08 | Foresite Labs, LLC | 10% Owner | Open Market Purchase | 294,117 | 17.00 | 4,999,989.00 | +424,2% | |
| 2026-01-08 | Foresite Labs, LLC | 10% Owner | Open Market Purchase | 117,647 | 17.00 | 1,999,999.00 | +169,7% | |
| 2026-01-08 | Foresite Capital Management VI LLC | 10% Owner | Open Market Purchase | 117,647 | 17.00 | 1,999,999.00 | +169,7% | |
| 2025-12-05 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 51,380 | 10.73 | 551,307.40 | +46,8% | |
| 2025-12-05 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 70,028 | 10.01 | 700,980.28 | +59,5% | |
| 2025-12-05 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 64,969 | 8.95 | 581,472.55 | +49,3% | |
| 2025-12-04 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 66,027 | 8.18 | 540,100.86 | +45,8% | |
| 2025-12-03 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 100,000 | 7.75 | 775,000.00 | +65,8% | |
| 2025-12-02 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 96,000 | 7.55 | 724,800.00 | +61,5% | |
| 2025-12-01 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 86,350 | 7.46 | 644,171.00 | +54,7% | |
| 2025-11-28 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 38,702 | 7.64 | 295,683.28 | +25,1% | |
| 2025-11-26 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 48,537 | 7.64 | 370,822.68 | +31,5% | |
| 2025-11-21 | Foresite Capital Management VI LLC | 10% Owner | Open Market Purchase | 72,212 | 7.38 | 532,924.56 | +45,2% | |
| 2025-11-21 | Tananbaum James B. | Director, 10% Owner | Open Market Purchase | 72,212 | 7.38 | 532,924.56 | +45,2% | |
| 2025-11-21 | Foresite Labs, LLC | 10% Owner | Open Market Purchase | 72,212 | 7.38 | 532,924.56 | +45,2% | |
| 2025-11-20 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 125,743 | 7.20 | 905,349.60 | +76,8% | |
| 2025-11-19 | Foresite Labs, LLC | 10% Owner | Open Market Purchase | 190,500 | 6.56 | 1,249,680.00 | +106,0% | |
| 2025-11-19 | Tananbaum James B. | Director, 10% Owner | Open Market Purchase | 190,500 | 6.56 | 1,249,680.00 | +106,0% | |
| 2025-11-19 | Foresite Capital Management VI LLC | 10% Owner | Open Market Purchase | 190,500 | 6.56 | 1,249,680.00 | +106,0% | |
| 2025-11-19 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 137,772 | 6.56 | 903,784.32 | +76,7% | |
| 2025-11-18 | Tananbaum James B. | Director, 10% Owner | Open Market Purchase | 117,374 | 6.19 | 726,545.06 | +61,6% | |
| 2025-11-18 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 102,652 | 6.05 | 621,044.60 | +52,7% | |
| 2025-11-18 | Foresite Labs, LLC | 10% Owner | Open Market Purchase | 117,374 | 6.19 | 726,545.06 | +61,6% | |
| 2025-11-18 | Foresite Capital Management VI LLC | 10% Owner | Open Market Purchase | 117,374 | 6.19 | 726,545.06 | +61,6% | |
| 2025-11-17 | Foresite Labs, LLC | 10% Owner | Open Market Purchase | 150,000 | 5.59 | 838,500.00 | +71,1% | |
| 2025-11-17 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 914 | 5.51 | 5,036.14 | +0,4% | |
| 2025-11-17 | Tananbaum James B. | Director, 10% Owner | Open Market Purchase | 50,000 | 5.60 | 280,000.00 | +23,8% | |
| 2025-11-17 | Tananbaum James B. | Director, 10% Owner | Open Market Purchase | 150,000 | 5.59 | 838,500.00 | +71,1% | |
| 2025-11-17 | Foresite Capital Management VI LLC | 10% Owner | Open Market Purchase | 50,000 | 5.60 | 280,000.00 | +23,8% | |
| 2025-11-17 | Foresite Capital Management VI LLC | 10% Owner | Open Market Purchase | 150,000 | 5.59 | 838,500.00 | +71,1% | |
| 2025-11-17 | Foresite Labs, LLC | 10% Owner | Open Market Purchase | 50,000 | 5.60 | 280,000.00 | +23,8% | |
| 2025-11-13 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 276,179 | 5.25 | 1,449,939.75 | +123,0% | |
| 2025-05-06 | Tananbaum James B. | Director, 10% Owner | Open Market Purchase | 20,000 | 4.34 | 86,800.00 | +7,4% | |
| 2025-05-06 | Foresite Capital Management VI LLC | 10% Owner | Open Market Purchase | 20,000 | 4.34 | 86,800.00 | +7,4% | |
| 2025-05-06 | Foresite Labs, LLC | 10% Owner | Open Market Purchase | 20,000 | 4.34 | 86,800.00 | +7,4% | |
| 2025-05-05 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 138,368 | 4.58 | 633,725.44 | +53,8% | |
| 2025-05-05 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 22,002 | 5.27 | 115,950.54 | +9,8% | |
| 2025-05-02 | Foresite Capital Management VI LLC | 10% Owner | Open Market Purchase | 25,000 | 4.62 | 115,500.00 | +9,8% | |
| 2025-05-02 | Foresite Labs, LLC | 10% Owner | Open Market Purchase | 25,000 | 4.62 | 115,500.00 | +9,8% | |
| 2025-05-02 | Tananbaum James B. | Director, 10% Owner | Open Market Purchase | 25,000 | 4.62 | 115,500.00 | +9,8% | |
| 2025-05-02 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 159,920 | 4.55 | 727,636.00 | +61,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.